InMed Pharmaceuticals Inc. · NASDAQ:INM
InMed Pharmaceuticals — Investor Presentation (February 2025)
24 slides from InMed Pharmaceuticals's investor presentation, February 2025
Slide 1: Corporate Presentation
Corporate Presentation February 2025 :INM www.inmedpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: anticipated development activities, timelines
Slide 3: Overview & Investment Highlights
Overview & Investment Highlights • Robust R&D pipeline with 3 candidates: - Alzheimer’s – multi-factorial approach, reduces neuroinflammation - Ocular – functional and pathological improvements for dry AMD - Dermatology - Phase 2 completed in EB, currently seeking partnerships • Library of proprieta
Slide 4: A Clinical Stage Pharmaceutical Company
A Clinical Stage Pharmaceutical Company A GLOBAL LEADER IN THE RESEARCH, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF RARE CANNABINOIDS Drug Discovery Pharmaceutical R&D Manufacturing Commercial • Pipeline of • Screening of therapeutic • Chemical and • B2B supplier to health pharmaceutical pr
Slide 5: Drug Development Programs
Drug Development Programs
Slide 6: Pharmaceutical Pipeline: Small Molecules Targeting CB1/CB2
Pharmaceutical Pipeline: Small Molecules Targeting CB1/CB2 HIGHLIGHTS SCREENING PRECLINICAL PH 1 PH 2 PH 3 • In vivo studies – improved neuronal function, neuroprotection, reduced neuroinflammation INM-9 01 • Improvement in cognitive function, memory, Alzheimer’s disease locomotor and anxiety-based
Slide 7: Alzheimer's Disease – A Major Medical & Societal Burden
Alzheimer’s Disease – A Major Medical & Societal Burden CURRENT TREATMENT OPTIONS DO NOT REVERSE EFFECTS What is Alzheimer’s Disease? Impact Alzheimer's is a subset of dementia that impacts • Alzheimer’s accounts for 60-80% the part of the brain that controls thought, memory of dementia cases and la
Slide 8: INM-901: A Multi-factorial Approach
INM-901: A Multi-factorial Approach A preferential signaling agonist Oral formulation that can for CB1/CB2 and impacts PPAR effectively pass the signaling pathways blood/brain barrier Increased neurite Demonstrated statistically outgrowth in in vitro significant reduction in studies, signifying INM-
Slide 9: INM-901: Potential Multiple Mechanisms of Action
INM-901: Potential Multiple Mechanisms of Action INM-901 INM-901 Cytotoxicity • Proprietary small Neuroinflammation molecule compound can cross BBB Neuroprotection • Can be formulated Neurite outgrowth orally Neuronal function • Preferential signaling Locomotion agonist for CB1/CB2 Memory • Impacts
Slide 10: INM-901 Demonstrates Multiple Pharmacological Effects
INM-901 Demonstrates Multiple Pharmacological Effects POTENTIAL TO TARGET SEVERAL BIOLOGICAL PATHWAYS ASSOCIATED WITH ALZHEIMER’S DISEASE Neuroprotection Neuritogenesis ALZ Behaviors • Amyloid-β-induced model • Measured neurite length • Basal and locomotor activity • Cytotoxicity and apoptosis compa
Slide 11: INM-901 Summary
INM-901 Summary Next Steps Research & Development • Small molecule, oral administration • Additional mRNA, protein and • In vitro: Neuroprotection and neuritogenesis histological measurements • Assess markers neuronal • In vivo: differentiation & function • 7 months of dosing, extended dosing durati
Slide 12: Impact of Dry Age-related Macular Degeneration (AMD)
Impact of Dry Age-related Macular Degeneration (AMD) LEADING CAUSE OF VISION LOSS What is AMD? AMD Opportunity AMD is an eye disease that can blur your • Affects 19.8M Americans central vision, eventually leading to loss aged 40+ of vision. It happens when aging causes • 12.6% of the U.S. population
Slide 13: AMD Occurs When the Macula is Damaged
AMD Occurs When the Macula is Damaged Back of eye Retina Retina (Macular Area) Damaged Photoreceptor macula at the cells back of the eye Retinal Pigment Epithelium Choroid Age-related Optic Macular Nerve Degeneration Dry AMD is the most common form of AMD. In the advanced stages of dry AMD, called G
Slide 14: INM-089: A Differentiated Approach to Treating Dry AMD
INM-089: A Differentiated Approach to Treating Dry AMD Ability to proactively A preferential signaling ligand protect the retinal for CB1 and CB2 ganglion cells Demonstrated promise in preserving retinal Improved the thickness of function in an INM-089 the outer nuclear layer of the retina where the
Slide 15: INM-089 Summary
INM-089 Summary Next steps Research & Development • Proprietary small molecule drug candidate • On-going dose-ranging studies • Deliverable via IVT formulation. Successful delivery at • Continuing CMC activities for drug doses up to 10 times the projected therapeutic level substance and drug product
Slide 16: INM-755 Cannabinol (CBN) Cream: Phase 2 Results in Itch
INM-755 Cannabinol (CBN) Cream: Phase 2 Results in Itch Conducted in Epidermolysis bullosa patients – a severe genetic dermatological disease with chronic, severe itch as a primary symptom. Key Results: Non-Wound Itch: Data breakdown Of the 18 participants assessed, chronic itch improved by a • A po
Slide 17: BayMedica Commercial Business
BayMedica Commercial Business
Slide 18: BayMedica - Wholesale Rare Cannabinoids for the H&W Market
BayMedica -Wholesale Rare Cannabinoids for the H&W Market HIGH PURITY, CONSISTENT & BIOIDENTICAL TO NATURE CBC CBDV THCV CBT Cannabichromene Cannabidivarin Tetrahydrocannabivarin Cannabicitran CONS IS TENC Y COST - EFFECTI VEN ESS High quality, bioidentical rare cannabinoids with exceptional Multipl
Slide 19: BayMedica Financial Performance
BayMedica Financial Performance Calendar Year Revenue Growth US$ (Fiscal year ends June 30) • Trailing 12-month revenue is $4.8M (000’s) 1,400 • Currently operating as a cash flow positive business 1,200 • 5 continuous quarters of stable revenues with 1,000 increased profitability 800 • ~$500K net i
Slide 20: Corporate
Corporate
Slide 21: Depth in Pharmaceutical R&D
Depth in Pharmaceutical R&D EXTENSIVE EXPERIENCE IN PHARMA DISCOVERY, DEVELOPMENT Eric A. Adams, MIBS Neeta Jagpal, CPA Michael Woudenberg, PEng Colin Clancy Shane Johnson, MD Chief Executive Officer Chief Financial Officer Chief Operating Officer VP, IR & Corp Comms SVP & GM, BayMedica 30+ years of
Slide 22: Fiscal 2025 – Key Value Drivers
Fiscal 2025 – Key Value Drivers • Develop INM-901 in ALZ long-term preclinical in vivo studies and manufacturing • Develop INM-089 in Dry AMD towards IND filing / human clinical trials • Evaluate INM-755 in chronic severe itch for clinical and commercial partnerships • Target proprietary cannabinoid
Slide 23: Financial Snapshot As of 2025-02-12
Financial Snapshot As of 2025-02-12 Cash and Short-term Investments $6.4 M(1) Shares I/O 1.2 M Options 62 K Warrants and Preferred Investment Options (478K @$16.60) 498 K Fully Diluted Shares 1.76 M Close $3.20 52-week High $15.60 52-week Low $2.40 Average Daily Volume (Trailing 50 Days) 583 K Marke
Slide 24: Thank you!
Thank you! Colin Clancy Vice President, Investor Relations & Corporate Communications [email protected] +1-604-416-0999 :INM www.inmedpharma.com
InMed Pharmaceuticals — Investor Presentation (February 2025) on 6ix